Clarus Therapeutics Holdings, Inc., recently announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover its oral testosterone replacement product, Jatenzo (testosterone undecanoate).
Related posts
-
Apartment developer launches Yorktown mall project; first phase calls for 271 units
Going into the busy holiday shopping season, visitors to Yorktown Center are seeing visible progress on... -
‘Patty is not a victim’: Patricia Columbo again denied parole for 1976 Elk Grove murders
Illinois’ Prisoner Review Board denies parole for Patricia Columbo, 68, who - along with her boyfriend... -
InterFaith Aurora to hold Thanksgiving, unity celebration
InterFaith Aurora will hold a Thanksgiving celebration Sunday at New England Congregational Church in Aurora. The...